• Thiazovivin ROCK Inhibitor Workflow Guide

  2026-10-01

  Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming for induced pluripotent stem cell generation and to improve human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, storage, and troubleshooting for in vitro stem cell research; it does not establish clinical use, diagnostic performance, or universal dosing.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-30

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and selected metabolic endpoints. It is suited to preclinical pathway interrogation, but its aqueous insolubility, formulation requirements, and limited clinical benefit make it inappropriate as a substitute for clinical efficacy evidence.

• 12-O-tetradecanoyl phorbol-13-acetate (TPA)

  2026-09-30

  This scenario-driven guide explains how 12-O-tetradecanoyl phorbol-13-acetate (TPA), SKU N2060, can help researchers control ERK/MAPK pathway activation while interpreting viability, proliferation, and cytotoxicity data. It covers solvent compatibility, timing, controls, storage, vendor selection, and the limitations of translating pathway responses into cell-death conclusions.

• Pexmetinib (ARRY-614): From Blockade to Control

  2026-09-29

  Pexmetinib (ARRY-614) illustrates how dual kinase targeting can connect cytokine suppression with deeper control of inflammatory signaling. This thought-leadership perspective translates p38 MAPK and Tie2 biology, emerging dephosphorylation concepts, assay design, and translational strategy for inflammation and myelodysplastic syndromes research.

• U0126 MEK1/2 Inhibitor: Pain-Pathway Workflows

  2026-09-29

  U0126 enables controlled MEK1/2 inhibition to separate ERK-dependent signaling from the ROS–p38 mechanisms described in orofacial neuropathic pain. This workflow-focused guide covers dose finding, phospho-protein readouts, autophagy assays, and troubleshooting for neurobiology and cancer biology research.

• In Situ CAR-M Design for Hepatocellular Carcinoma

  2026-09-28

  The reference study develops an in situ programmed CAR-macrophage strategy that combines GPC3 recognition with self-secreted IFN-γ and a dominant-negative SIRPα extracellular domain. Using lipid nanoparticle-encapsulated mRNA, the authors report enhanced macrophage inflammatory activity, phagocytosis, tumor-microenvironment remodeling, and activity against human hepatocellular carcinoma organoids.

• H-89 for PKA-Linked Wnt and Osteogenesis Studies

  2026-09-28

  Use H-89 as a timed pharmacological probe to test whether PKA contributes to Wnt-linked signaling, while separating early pathway events from later metabolic and osteogenic outcomes. This workflow emphasizes dose titration, vehicle controls, and orthogonal validation so a change in cell phenotype is not mistaken for proof of PKA-specific action.

• Melanoma Multi-Omics Maps ARID1A-Linked Resistance

  2026-09-27

  An integrative multi-omics study maps early drug-response networks in BRAF-inhibitor-sensitive melanoma cells and an ARID1A-knockout resistant derivative. Its findings connect persistent MAPK and JUN signaling, altered PRKD1 and NCK1 network activity, and changes in immune- and extracellular-matrix-related proteins, suggesting testable routes for studying resistance.

• ARID1A-Dependent Melanoma Resistance: Multi-Omics Insights

  2026-09-26

  An integrative study compares early drug responses in BRAF V600E-sensitive melanoma cells and an ARID1A-knockout derivative, identifying a resistance-associated network involving MAPK, JNK, PRKD1, JUN, and NCK1. Its findings frame resistance as coordinated signaling and cellular-state adaptation, while offering candidate nodes for further validation rather than established therapeutic targets.

• H-89 in Wnt-Driven Bone Metabolism

  2026-09-25

  Wnt signaling can promote bone formation by connecting PKA activity with O-GlcNAcylation and glycolysis. This article examines how H-89 can help translational researchers test that connection—while emphasizing the controls needed to distinguish PKA-dependent effects from broader cellular responses.

• Tomivosertib and the Translational Control Opportunity

  2026-09-25

  A translational framework for using Tomivosertib to test how MNK1/2-dependent eIF4E phosphorylation shapes tumor-cell phenotypes—while separating target engagement from biological effect.

• p-Cresyl sulfate: Assay Design for CKD Research

  2026-09-24

  A practical guide to using p-Cresyl sulfate (SKU A8895) in viability, proliferation, endothelial repair, and vascular calcification studies. It connects assay interpretation and handling choices to published data while distinguishing established findings from workflow recommendations.

• GDC-0994: ERK1/2 Beyond Oncology

  2026-09-24

  ERK1/2 is a convergence point in tumor biology and, as new zebrafish evidence suggests, estrogen-associated cholestatic injury. Explore how GDC-0994 can help translational researchers test pathway dependence while keeping cross-model claims appropriately bounded.

• AZD8055: Practical Guide to mTOR Inhibition

  2026-09-23

  AZD8055 is an ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling in cell and preclinical models. It is useful for pathway-dissection experiments, but its poor water solubility and limited clinical benefit make it unsuitable as a clinical-efficacy proxy or for workflows requiring aqueous stock solutions.

• HIV-1 Nuclear Pore Remodeling Licences T-Cell Infection

  2026-09-23

  The reference study identifies nuclear pore complex remodeling as a key bottleneck that HIV-1 overcomes during cell–cell spread in resting T cells. By combining engineered virus systems, primary-cell assays, and super-resolution imaging, it links virological-synapse contact to CD4–LCK–CDK1 signaling, nucleoporin phosphorylation, and enhanced capsid nuclear import.

8498 records 1/567 page Next 12345 下5页 Last page